Literature DB >> 31407028

Alpha-synuclein: prion or prion-like?

Rehana K Leak1, Matthew P Frosch2, Thomas G Beach3, Glenda M Halliday4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31407028      PMCID： PMC6778512          DOI： 10.1007/s00401-019-02057-1

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN： 0001-6322            Impact factor:   17.088


× No keyword cloud information.
  51 in total

1.  Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective.

Authors:  Mikiei Tanaka; Yong Man Kim; Gwang Lee; Eunsung Junn; Takeshi Iwatsubo; M Maral Mouradian
Journal:  J Biol Chem       Date:  2003-11-19       Impact factor: 5.157

Review 2.  Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages).

Authors:  Heiko Braak; Kelly Del Tredici; Hansjürgen Bratzke; John Hamm-Clement; Daniele Sandmann-Keil; Udo Rüb
Journal:  J Neurol       Date:  2002-10       Impact factor: 4.849

Review 3.  Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit.

Authors:  Will C Guest; J Maxwell Silverman; Edward Pokrishevsky; Megan A O'Neill; Leslie I Grad; Neil R Cashman
Journal:  J Toxicol Environ Health A       Date:  2011

4.  Transfer of host-derived α synuclein to grafted dopaminergic neurons in rat.

Authors:  Jeffrey H Kordower; Hemraj B Dodiya; Adam M Kordower; Brian Terpstra; Katrina Paumier; Lalitha Madhavan; Caryl Sortwell; Kathy Steece-Collier; Timothy J Collier
Journal:  Neurobiol Dis       Date:  2011-05-12       Impact factor: 5.996

5.  Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice.

Authors:  Kelvin C Luk; Victoria Kehm; Jenna Carroll; Bin Zhang; Patrick O'Brien; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2012-11-16       Impact factor: 47.728

6.  Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia.

Authors:  Laura Parkkinen; Tarja Kauppinen; Tuula Pirttilä; Jaana M Autere; Irina Alafuzoff
Journal:  Ann Neurol       Date:  2005-01       Impact factor: 10.422

7.  Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject.

Authors:  Laura Parkkinen; Tuula Pirttilä; Markku Tervahauta; Irina Alafuzoff
Journal:  Neuropathology       Date:  2005-12       Impact factor: 1.906

Review 8.  Effects of α-synuclein on axonal transport.

Authors:  Laura A Volpicelli-Daley
Journal:  Neurobiol Dis       Date:  2016-12-09       Impact factor: 5.996

9.  Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease.

Authors:  Laura Parkkinen; Sean S O'Sullivan; Catherine Collins; Aviva Petrie; Janice L Holton; Tamas Revesz; Andrew J Lees
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

Review 10.  Is there a risk of prion-like disease transmission by Alzheimer- or Parkinson-associated protein particles?

Authors:  Michael Beekes; Achim Thomzig; Walter J Schulz-Schaeffer; Reinhard Burger
Journal:  Acta Neuropathol       Date:  2014-07-30       Impact factor: 17.088
View more
  5 in total

1.  Can the lack of fibrillar form of alpha-synuclein in Lewy bodies be explained by its catalytic activity?

Authors:  Ivan A Kuznetsov; Andrey V Kuznetsov
Journal:  Math Biosci       Date:  2021-12-07       Impact factor: 2.144

2.  Disruption of cellular proteostasis by H1N1 influenza A virus causes α-synuclein aggregation.

Authors:  Rita Marreiros; Andreas Müller-Schiffmann; Svenja V Trossbach; Ingrid Prikulis; Sebastian Hänsch; Stefanie Weidtkamp-Peters; Ana Raquel Moreira; Shriya Sahu; Irina Soloviev; Suganya Selvarajah; Vishwanath R Lingappa; Carsten Korth
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-09       Impact factor: 11.205

Review 3.  α-Synuclein Conformational Plasticity: Physiologic States, Pathologic Strains, and Biotechnological Applications.

Authors:  Amanda Li; Cyrus Rastegar; Xiaobo Mao
Journal:  Biomolecules       Date:  2022-07-17

Review 4.  Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?

Authors:  Victoria Sidoroff; Pam Bower; Nadia Stefanova; Alessandra Fanciulli; Iva Stankovic; Werner Poewe; Klaus Seppi; Gregor K Wenning; Florian Krismer
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

5.  A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies.

Authors:  Maike Hartlage-Rübsamen; Alexandra Bluhm; Sandra Moceri; Lisa Machner; Janett Köppen; Mathias Schenk; Isabel Hilbrich; Max Holzer; Martin Weidenfeller; Franziska Richter; Roland Coras; Geidy E Serrano; Thomas G Beach; Stephan Schilling; Stephan von Hörsten; Wei Xiang; Anja Schulze; Steffen Roßner
Journal:  Acta Neuropathol       Date:  2021-07-26       Impact factor: 17.088
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.